About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: March 2010
The State of the News Media Report, Implications for Pharma and FDA, Part 2
Yesterday the Pew Project for Excellence in Journalism released its annual State of the Media report. Within its 700 pages of information, there is a lot that can be discerned about how the way we communicate is changing – is … Continue reading
Posted in Uncategorized
1 Comment
The State of the News Media Report – Implications for Pharma and FDA, Part 1
Each year, the Pew Project for Excellence in Journalism releases a report on the state of the news media. It is packed with information and views about how media is rapidly being transformed. For medical product manufacturers such as pharmaceutical … Continue reading
Posted in Uncategorized
1 Comment
Yahoo! Submits Document to FDA Social Media Docket and Status of Submissions
Is FDA still listening about social media and medical products? The deadline has passed (February 28), but a new submission was posted – this time from Yahoo! to the FDA's Social Media Docket that was set up in the wake … Continue reading
Posted in Uncategorized
2 Comments
Facebook and Web Pages – What Pharma and FDA Need to Know
Recently, people have noticed an important milestone. The top traffic referral site is …. Google? Nope. Yahoo? Nope. It is Facebook. What? That's crazy talk! Apparently not. And not only is it tops in terms of numbers, according to … Continue reading
Posted in Uncategorized
4 Comments
Interesting History at FDA as Alliance for a Stronger FDA Goes to Bat for Bigger Agency Budget
The Alliance for a Stronger FDA had an interesting blog posting on Friday called "Top Ten Things that Hill Staff Need to Know About FDA" in preparation for their upcoming Hill Lobby Day to be held March 11. In case you … Continue reading
Posted in Uncategorized
Comments Off on Interesting History at FDA as Alliance for a Stronger FDA Goes to Bat for Bigger Agency Budget